Share This

Public company info - Acotec Scientific Holdings Limited , 06669.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Acotec Scientific Holdings Limited, 06669.HK - Company Profile
Chairman Jing LI
Share Issued (share) 313,000,000
Par Currency U.S. Dollar
Par Value 1.0E-5
Industry -
Corporate Profile Business Summary: The group is a leading innovative medical device company in China focusing on providing “leave nothing behind” treatment solutions for vascular diseases. Performance for the year: In 2019 and 2020, the group’s revenue from sales of products amounted to RMB124.9 million and RMB194.0 million, respectively. Business Review The group have developed a suite of interventional medical devices featuring world-leading technologies, notably in the fields of drug-coated balloons (DCB) and thrombus aspiration catheters. the group developed and launched the first peripheral DCB product in China in 2016, approximately four years ahead of the closest runner-up, and had a dominating market share of approximately 86.9% in the peripheral DCB market in China in terms of revenue generated in 2020. the group’s second DCB product was designated as a “breakthrough device” by the FDA in 2019 as it provides for more effective treatment in irreversibly debilitating human conditions and offers significant advantages over existing approved or cleared alternative medical devices. The designation also indicates that the product represents breakthrough technology and its availability is in the best interest of patients. After the designation, the product was entitled to an expedited process of the development, assessment, and review by the FDA. The product also obtained the NMPA approval in December 2020, making it the world’s first (and, as of the Latest Practicable Date, only) below-the-knee (BTK) DCB product receiving regulatory approval based on multi-center randomized controlled clinical trial results. the group’s DCB products feature one of the most advanced drug-coating technologies among all the DCB products worldwide, and had demonstrated good clinical performance based on the results of the clinical trials conducted by us for such products. The group is also in the process of developing a comprehensive product pipeline, with 24 product candidates in various stages of development as of the Latest Practicable Date. the group believe the group’s first-mover advantages, world-leading technologies, dominating market share in China, and comprehensive product pipeline established high entry barriers difficult for the group’s competitors to surpass. the group’s mission is to become a global leader that provides full-suite “leave nothing behind” interventional solutions for vascular diseases. Interventional treatment of vascular diseases caused by atherosclerosis is regarded as one of the most innovative fields of modern medical research, according to Frost & Sullivan. In recent years, the growing prevalence of vascular diseases caused by atherosclerosis such as peripheral artery disease (PAD), coronary artery disease (CAD), and stroke boosted the adoption of minimally invasive interventional procedures worldwide. Treatment solutions used in these interventional procedures have evolved from percutaneous transluminal angioplasty (PTA) balloons to stents, and further to DCBs. The major drawback of PTA balloons is the high incidence of short-term vessel restenosis. Stents are effective in preventing vessel restenosis, but may cause complications such as thrombosis, stent fracture, and in-stent restenosis (ISR). DCB therapy is an innovative therapy using angioplasty balloons coated with anti-proliferative drugs. As compared to PTA balloons, DCB can effectively inhibit neointimal hyperplasia, thereby reducing the risks of vessel restenosis. As compared to stenting, DCB therapy can significantly reduce the risk of thrombosis, avoid stent fracture and ISR, and more importantly, offers a unique value proposition of “leaving nothing behind” in human bodies. As a result of such benefits, DCBs are becoming increasingly popular and have been progressively replacing stents in vascular interventions, according to Frost & Sullivan. The concept of DCB therapy was first envisioned by the group’s CTO, Dr. Ulrich Speck, who invented the first DCB product in the world, the drug-coating technology used in B. Braun’s SeQuent Please, the world’s No. 1 coronary DCB product in terms of sales volume up to the Latest Practicable Date, as well as the drug-coating technology used in Medtronic’s IN.PACT, the world’s No. 1 peripheral DCB product in terms of sales volume up to the Latest Practicable Date, according to Frost & Sullivan. Thereafter, Dr. Speck made several other breakthrough discoveries in drug-coating technology, which the group use in the group’s DCB products and product candidates. As of the Latest Practicable Date, the group had two DCB products approved by the NMPA. • AcoArt Orchid® & DhaliaTM, the group’s Core Product, is indicated for treating superficial femoral artery (SFA) and popliteal artery (PPA) lesions. AcoArt Orchid® & DhaliaTM was approved by the NMPA in May 2016, approximately four years ahead of the closest runner-up. the group started to sell AcoArt Orchid® in China since June 2016 and AcoArt DhaliaTM in China since August 2016. As of the [May 27, 2021], the group had launched AcoArt Orchid® & DhaliaTM in China and AcoArt Orchid® in eleven other countries, including medically-advanced countries such as Germany, Italy and Switzerland. • AcoArt TulipTM & LitosTM, the group’s Core Product, is indicated for treating BTK lesions. the group obtained the NMPA approval for AcoArt TulipTM & LitosTM through a fast-track program in December 2020. the group started to sell AcoArt TulipTM & LitosTM in China since January 2021. According to Frost & Sullivan, as of the Latest Practicable Date, AcoArt TulipTM & LitosTM was the only BTK DCB product approved by the NMPA, and there was no ongoing clinical trial conducted in China for any other BTK DCB product candidates. the group expect that the group can maintain the group’s leading position in the BTK DCB market in China for at least five years considering that AcoArt TulipTM & LitosTM was the first BTK DCB approved for market in China, and as of the Latest Practicable Date, there was no ongoing clinical trial conducted in China for any other BTK DCB product candidates. AcoArt LitosTM was designated as a “breakthrough device” by the FDA in 2019, and was the first (and, as of the Latest Practicable Date, one of the only three) domestically-manufactured device(s) receiving such designation, according to Frost & Sullivan. As of the [May 27, 2021], the group had launched AcoArt TulipTM & LitosTM in China and ten other countries including Germany, Italy and Switzerland. The group is also a pioneer in expanding indications of DCB products. According to Frost & Sullivan, the narrowing of arteries may result in different types of diseases. Depending on the different arteries affected, such diseases include CAD, PAD, stroke, arteriovenous fistula (AVF) stenosis in hemodialysis (HD) patients and erectile dysfunction. DCB therapy, as a proven therapy for the treatment of CAD and PAD, is a promising therapy for treating these other types of vascular diseases. The group is actively exploring the opportunities to expand the indications of the group’s Core Products to nephrology, neurology and andrology, to address the unmet or underserved clinical needs of patients suffering from other types of vascular diseases, such as arteriovenous fistula (AVF) stenosis, vertebral atherosclerotic stenosis and erectile dysfunction. However, the group may not be able to ultimately develop and market the group’s Core Products indicated for these diseases successfully. With the group’s strong research and development capabilities, accumulated experience in product registration, and the group’s established commercialization network, the group believe that the group can efficiently replicate the group’s success in the lower extremity DCB market, and capture the growth potential of the large and fast growing vascular disease treatment market in China. The group is also offering and developing many other therapeutic, procedural and ancillary medical devices such as thrombus aspiration devices and radiofrequency systems. Prospects: Leveraging on the group’s strengths, the group plan to implement the following strategies to achieve the group’s mission: • leverage the synergistic effects from the group’s four core technologies to further expand the group’s product offerings; • continue to grow sales of AcoArt Orchid® & DhaliaTM; • rapidly advance the clinical development and commercialization of late-staged product candidates; • expand the group’s geographic presence and worldwide footprint to become a global leader; and • strengthen the group’s research and development capabilities and expand manufacturing capacities.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.